Management of osteoporosis in the aging male: focus on zoledronic acid.

Paul K. Piper, Ugis Gruntmanis

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Osteoporosis in the aging male remains an important yet under-recognized and undertreated disease. Current US estimates indicate that over 14 million men have osteoporosis or low bone mass, and men suffer approximately 500,000 osteoporotic fractures each year. Men experience fewer osteoporotic fractures than women but have higher mortality after fracture. Bisphosphonates are potent antiresorptive agents that inhibit osteoclast activity, suppress in vivo markers of bone turnover, increase bone mineral density, decrease fractures, and improve survival in men with osteoporosis. Intravenous zoledronic acid may be a preferable alternative to oral bisphosphonate therapy in patients with cognitive dysfunction, the inability to sit upright, or significant gastrointestinal pathology. Zoledronic acid (Reclast) is approved in the US as an annual 5 mg intravenous infusion to treat osteoporosis in men. The zoledronic acid (Zometa) 4 mg intravenous dose has been studied in the prevention of bone loss associated with androgen deprivation therapy.

Original languageEnglish (US)
Pages (from-to)289-303
Number of pages15
JournalClinical Interventions in Aging
Volume4
StatePublished - 2009

Fingerprint

zoledronic acid
Osteoporosis
Osteoporotic Fractures
Diphosphonates
Bone Density Conservation Agents
Bone and Bones
Bone Remodeling
Osteoclasts
Intravenous Infusions
Bone Density
Androgens
Pathology

ASJC Scopus subject areas

  • Geriatrics and Gerontology

Cite this

Management of osteoporosis in the aging male : focus on zoledronic acid. / Piper, Paul K.; Gruntmanis, Ugis.

In: Clinical Interventions in Aging, Vol. 4, 2009, p. 289-303.

Research output: Contribution to journalArticle

Piper, Paul K. ; Gruntmanis, Ugis. / Management of osteoporosis in the aging male : focus on zoledronic acid. In: Clinical Interventions in Aging. 2009 ; Vol. 4. pp. 289-303.
@article{25b3d9ff9b1e4743a6810d47848152d3,
title = "Management of osteoporosis in the aging male: focus on zoledronic acid.",
abstract = "Osteoporosis in the aging male remains an important yet under-recognized and undertreated disease. Current US estimates indicate that over 14 million men have osteoporosis or low bone mass, and men suffer approximately 500,000 osteoporotic fractures each year. Men experience fewer osteoporotic fractures than women but have higher mortality after fracture. Bisphosphonates are potent antiresorptive agents that inhibit osteoclast activity, suppress in vivo markers of bone turnover, increase bone mineral density, decrease fractures, and improve survival in men with osteoporosis. Intravenous zoledronic acid may be a preferable alternative to oral bisphosphonate therapy in patients with cognitive dysfunction, the inability to sit upright, or significant gastrointestinal pathology. Zoledronic acid (Reclast) is approved in the US as an annual 5 mg intravenous infusion to treat osteoporosis in men. The zoledronic acid (Zometa) 4 mg intravenous dose has been studied in the prevention of bone loss associated with androgen deprivation therapy.",
author = "Piper, {Paul K.} and Ugis Gruntmanis",
year = "2009",
language = "English (US)",
volume = "4",
pages = "289--303",
journal = "Clinical Interventions in Aging",
issn = "1176-9092",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Management of osteoporosis in the aging male

T2 - focus on zoledronic acid.

AU - Piper, Paul K.

AU - Gruntmanis, Ugis

PY - 2009

Y1 - 2009

N2 - Osteoporosis in the aging male remains an important yet under-recognized and undertreated disease. Current US estimates indicate that over 14 million men have osteoporosis or low bone mass, and men suffer approximately 500,000 osteoporotic fractures each year. Men experience fewer osteoporotic fractures than women but have higher mortality after fracture. Bisphosphonates are potent antiresorptive agents that inhibit osteoclast activity, suppress in vivo markers of bone turnover, increase bone mineral density, decrease fractures, and improve survival in men with osteoporosis. Intravenous zoledronic acid may be a preferable alternative to oral bisphosphonate therapy in patients with cognitive dysfunction, the inability to sit upright, or significant gastrointestinal pathology. Zoledronic acid (Reclast) is approved in the US as an annual 5 mg intravenous infusion to treat osteoporosis in men. The zoledronic acid (Zometa) 4 mg intravenous dose has been studied in the prevention of bone loss associated with androgen deprivation therapy.

AB - Osteoporosis in the aging male remains an important yet under-recognized and undertreated disease. Current US estimates indicate that over 14 million men have osteoporosis or low bone mass, and men suffer approximately 500,000 osteoporotic fractures each year. Men experience fewer osteoporotic fractures than women but have higher mortality after fracture. Bisphosphonates are potent antiresorptive agents that inhibit osteoclast activity, suppress in vivo markers of bone turnover, increase bone mineral density, decrease fractures, and improve survival in men with osteoporosis. Intravenous zoledronic acid may be a preferable alternative to oral bisphosphonate therapy in patients with cognitive dysfunction, the inability to sit upright, or significant gastrointestinal pathology. Zoledronic acid (Reclast) is approved in the US as an annual 5 mg intravenous infusion to treat osteoporosis in men. The zoledronic acid (Zometa) 4 mg intravenous dose has been studied in the prevention of bone loss associated with androgen deprivation therapy.

UR - http://www.scopus.com/inward/record.url?scp=77950501905&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950501905&partnerID=8YFLogxK

M3 - Article

C2 - 19750231

AN - SCOPUS:77950501905

VL - 4

SP - 289

EP - 303

JO - Clinical Interventions in Aging

JF - Clinical Interventions in Aging

SN - 1176-9092

ER -